Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American So...
November 06 2019 - 8:15AM
Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical
company focused on developing and commercializing novel cancer
therapeutics that reactivate mutant tumor suppressor protein p53,
today announced that it will present updated data from two Phase
1b/2 clinical studies at 61st American Society of Hematology Annual
Meeting (ASH) on December 9, 2019. Data from the US Phase 1b/2
Trial and interim results from the French Phase 1b/2 Trial for its
lead candidate APR-246 in combination with Azacitidine (AZA) in
patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute
Myeloid Leukemia (AML) were both chosen for oral presentations.
Details of the oral presentations are as follows:
Title: Phase 2 Results of APR-246 and
Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic
Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia
(AML)Date & Time: Monday, December 9, 2019 at
11:15 am ETOral Abstract Session: 637.
Myelodysplastic Syndromes—Clinical Studies: Targeting Gene
Mutations in MDSAbstract:
676Location: Orange County Convention Center,
W311ABCDPresenter: David A Sallman, M.D.,
Assistant Member, Malignant Hematology Department H. Lee Moffitt
Cancer Center and Research Institute Tampa, Florida
Title: APR-246 combined with Azacitidine (AZA)
in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML). A phase 2 study by the Groupe Francophone des
Myélodysplasies (GFM)Date & Time: Monday,
December 9, 2019 at 11:30 am ETOral Abstract
Session: 637. Myelodysplastic Syndromes—Clinical Studies:
Targeting Gene Mutations in MDSAbstract:
677Location: Orange County Convention Center,
W311ABCDPresenter: Thomas Cluzeau, M.D., Ph.D.,
Professor, Department of Clinical Hematology, Cote d’Azur
University, Nice, France
Details of the Company’s Clinical Update meeting and webcast are
as follows:
Time and Date: Monday, December 9 at 12:00 pm
ETLocation: Hyatt Regency Orlando, Rainbow Spring
2 Room, 9801 International Drive, Orlando,
FloridaWebcast: The Clinical Update meeting will
be webcast live and can be accessed from "Events Calendar" in the
News and Events section of the company's website
at LinkPresentation: The presentation will be
available as a PDF on the Company’s website at Link
About Aprea Therapeutics, Inc.
Aprea Therapeutics Inc., (NASDAQ: APRE) is a
biopharmaceutical company headquartered in Boston, Massachusetts
with research facilities in Stockholm, Sweden, focused on
developing and commercializing novel cancer therapeutics that
reactivate mutant tumor suppressor protein, p53. The Company’s lead
product candidate is APR-246, a small molecule in clinical
development for hematologic malignancies, including myelodysplastic
syndromes (MDS) and acute myeloid leukemia (AML).
Forward Looking Statements
This press release includes forward-looking statements within
the meaning of the federal securities laws. Forward-looking
statements involve known and unknown risks, uncertainties,
assumptions and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. The forward-looking statements
contained in this press release reflect Aprea’s current views with
respect to future events, and Aprea does not undertake and
specifically disclaims any obligation to update any forward-looking
statements.
Corporate Contacts:
Christian S. Schade
President and Chief Executive Officer
chris.schade@aprea.com
Gregory A. Korbel, Ph.D.
Vice President of Business Development
greg.korbel@aprea.com
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jul 2023 to Jul 2024